Obesity drugmakers Orexigen, Vivus continue to falter

Bad news for struggling obesity drugmakers: Things aren't going to get any better, one analyst says. And the way he sees it, for leaders Orexigen ($OREX) and Vivus ($VVUS), they're likely to get much worse. More from FiercePharmaMarketing

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.